Linden Thomas Advisory Services’s Corcept Therapeutics CORT Stock Holding History

Linden Thomas Advisory Services’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.01M	Sell	34,641 -26,609	-43%	-$1.61M	0.24%	127
2026 Q1	$2.47M	Sell	61,250 -1,960	-3%	-$73.3K	0.24%	137
2025 Q4	$2.2M	Sell	63,210 -695	-1%	-$54.6K	0.22%	131
2025 Q3	$5.31M	Buy	63,905 +305	+0.5%	+$22.1K	0.54%	34
2025 Q2	$4.67M	Sell	63,600 -92	-0.1%	-$6.67K	0.51%	37
2025 Q1	$7.27M	Buy	63,692 +468	+0.7%	+$28.5K	0.94%	5
2024 Q4	$3.19M	Buy	63,224 +1,300	+2%	+$68.1K	0.4%	52
2024 Q3	$2.87M	Buy	61,924 +1,051	+2%	+$37.3K	0.39%	57
2024 Q2	$1.98M	Buy	60,873 +2,002	+3%	+$54.8K	0.31%	94
2024 Q1	$1.48M	Buy	58,871 +2,200	+4%	+$52K	0.24%	171
2023 Q4	$1.84M	Buy	56,671 +555	+1%	+$15.2K	0.34%	86
2023 Q3	$1.53M	Buy	56,116 +368	+0.7%	+$10.7K	0.34%	100
2023 Q2	$1.24M	Buy	+55,748	New	+$1.28M	0.28%	142

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Linden Thomas Advisory Services's CORT Position: Q2 2026 in Review

Linden Thomas Advisory Services reduced its Corcept Therapeutics (CORT) stake by 43% in Q2 2026, selling an estimated $1.61M and leaving 34,641 shares worth $3.01M. The position accounts for 0.24% of the portfolio, ranked #127.

Linden Thomas Advisory Services first reported a position in CORT in Q2 2023 and has held it in 13 quarters since. The position peaked at $7.27M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Linden Thomas Advisory Services held 34,641 shares of Corcept Therapeutics worth $3.01M as of Q2 2026.
Linden Thomas Advisory Services sold 26,609 Corcept Therapeutics shares in Q2 2026, an estimated $1.61M.
Corcept Therapeutics made up 0.24% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #127 holding.
Linden Thomas Advisory Services first reported a position in Corcept Therapeutics in Q2 2023 and has held it in 13 quarters since.
Linden Thomas Advisory Services's Corcept Therapeutics position peaked at $7.27M in Q1 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.